FDA grants priority review status to Gilead's hepatitis C drug

June 7 Fri Jun 7, 2013 6:08pm EDT

June 7 (Reuters) - Biotechnology company Gilead Sciences Inc said the U.S. Food and Drug Administration (FDA) granted priority review to its experimental hepatitis C drug sofosbuvir.

The FDA grants priority reviews to medicines that are considered potentially significant therapeutic advancements over existing therapies.

The FDA set a review date of Dec. 8 for the drug, Gilead said.

Gilead's oral drug is considered the most advanced and high-profile of treatments free of interferon, a standard hepatitis C drug which has side effects including colds and muscle fatigue.

Drugmakers AbbVie and Bristol-Myers Squibb are also developing such treatments but they require patient to take more pills each day than Gilead's treatment.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.